Dr. Vaena on the Importance of Risk Stratification in Prostate Cancer

Daniel Vaena, MD
Published: Monday, Dec 10, 2018



Daniel Vaena, MD, medical oncologist and hematologist, West Cancer Center, discusses the importance of risk stratification in prostate cancer.

It is important to remember that patients need to be carefully selected for treatment based on risk stratification, says Vaena. There are many new therapeutic agents available to patients with metastatic disease and castration-naïve disease; however, risk stratification can help physicians understand the potential benefits of each therapy. In the most recent trials conducted to date, patients were stratified based on burden of disease.

As there is no uniform rule for how patients should be treated, it is important to acknowledge a patient’s burden of disease before proceeding with therapy. The same holds true for patients with nonmetastatic prostate cancer, adds Vaena. Trials performed in this patient population selected treatment based on several features, including prostate specific antigen doubling times. The current recommendations and approvals do not necessarily apply to all patients with nonmetastatic disease, Vaena warns.
SELECTED
LANGUAGE


Daniel Vaena, MD, medical oncologist and hematologist, West Cancer Center, discusses the importance of risk stratification in prostate cancer.

It is important to remember that patients need to be carefully selected for treatment based on risk stratification, says Vaena. There are many new therapeutic agents available to patients with metastatic disease and castration-naïve disease; however, risk stratification can help physicians understand the potential benefits of each therapy. In the most recent trials conducted to date, patients were stratified based on burden of disease.

As there is no uniform rule for how patients should be treated, it is important to acknowledge a patient’s burden of disease before proceeding with therapy. The same holds true for patients with nonmetastatic prostate cancer, adds Vaena. Trials performed in this patient population selected treatment based on several features, including prostate specific antigen doubling times. The current recommendations and approvals do not necessarily apply to all patients with nonmetastatic disease, Vaena warns.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x